Term ends May 1, 2031 · Medium confidence
20-year base term ends Nov 24, 2030
Why Medium: A parent in the chain could not be resolved.
Held by MedImmune Limited
Filed May 6, 2014 as application 14/271,108 · Granted Nov 15, 2016
Base term plus 218 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2010
2031
Clock starts
Nov 24, 2010
Nov 24, 2010
Term ends
May 1, 2031
May 1, 2031
Granted
Nov 15, 2016
Nov 15, 2016
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
218
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,779,108.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 218 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 24, 2010, when application PCT/US2010/058007, the earliest non-provisional in its chain, was filed (this one was filed May 6, 2014); a parent in its chain could not be resolved (the next row) | Nov 24, 2030 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +218 days, USPTO patent term adjustment record | Jun 30, 2031 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,779,108) | capped to Nov 24, 2030 | High confidence |
| Patent term extension | +158 days, USPTO 35 U.S.C. 156 certificate | added to Nov 24, 2030: May 1, 2031 | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 1, 2031 | Medium confidence |
This family
| US 8,779,108 | In force Nov 2030 | Nov 2030 |
| US 9,493,565 | this patent May 2031 | May 2031 |
| US 10,400,039 | In force Nov 2030 | Nov 2030 |
| US 11,518,809 | In force Nov 2030 | Nov 2030 |
| US 12,686,718 | In force Jun 2031 | Jun 2031 |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 5, 2016 Reel 39073, frame 889 | Hammond, Scott; Mulgrew, Kathleen Ann | MedImmune, LLC | Assignment of Assignor's Interest |
| Jul 5, 2016 Reel 39074, frame 31 | Queva, Christophe; Babcook, John; Foltz, Ian Nevin; Kang, Jaspal Singh; Sekirov, Laura | Amgen British Columbia | Assignment of Assignor's Interest |
| Jul 5, 2016 Reel 39074, frame 87 | Morrow, Michelle; Boyle, Melanie; Chodorge, Matthieu; Stewart, Ross A. | MedImmune Limited | Assignment of Assignor's Interest |
| Jul 5, 2016 Reel 39074, frame 116 | Alimzhanov, Marat | AstraZeneca AB | Assignment of Assignor's Interest |
| Jul 5, 2016 Reel 39255, frame 379 | Amgen British Columbia | MedImmune Limited | Assignment of Assignor's Interest |
| Jul 5, 2016 Reel 39255, frame 468 | MedImmune, LLC | MedImmune Limited | Assignment of Assignor's Interest |
| Jul 5, 2016 Reel 39255, frame 471 | AstraZeneca AB | MedImmune Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2031
Term ends May 1, 2031. Maintenance fees still fall due before then
Note
The 218 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,779,108.
Citations
15
later US patents cite this one
That is top 25% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.